Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for PTCT
| Stock Name | PTC Therapeutics Inc |
| Ticker | PTCT(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US69366J2006 |
| LEI | 549300UJLWOIWFDGB318 |
Show aggregate PTCT holdings
News associated with PTCT
- Bank of America Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective reduced by Bank of America from $82.00 to $76.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on PTCT. Wall Street Zen lowered PTC Therapeutics from a […] - 2025-08-21 04:58:55
- PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $73.00 at Wells Fargo & Company
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective trimmed by Wells Fargo & Company from $79.00 to $73.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Cantor Fitzgerald increased their […] - 2025-08-21 04:58:48
- Noteworthy Monday Option Activity: ADBE, PTCT, RUM
- Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 32,627 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 95.9% of - 2025-08-11 16:29:24
- Natixis Advisors LLC Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
- Natixis Advisors LLC increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,220 shares of the biopharmaceutical company’s stock after buying an additional 3,160 shares during the quarter. Natixis […] - 2025-08-11 05:47:02
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
- Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy […] - 2025-08-11 05:11:00
- PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $80.00
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target lifted by UBS Group from $71.00 to $80.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of several other reports. Citigroup increased their target price on shares of PTC […] - 2025-08-01 05:49:00
- PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective lifted by Cantor Fitzgerald from $112.00 to $120.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2025 earnings at $8.16 EPS and FY2026 earnings […] - 2025-08-01 05:48:59
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong Ltd
- Y Intercept Hong Kong Ltd lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 54.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,981 shares of the biopharmaceutical company’s stock after selling 6,043 shares during the quarter. Y Intercept Hong […] - 2025-07-31 04:39:00
- Truist Financial Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective increased by Truist Financial from $80.00 to $86.00 in a report published on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of a number of other research reports. Wells Fargo & Company lifted […] - 2025-07-30 05:06:48
- Bank of America Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target increased by Bank of America from $68.00 to $84.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on the company. Royal Bank […] - 2025-07-30 04:22:59
- Barclays Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
- PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective upped by Barclays from $42.00 to $46.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on PTCT. Robert W. Baird lowered their price objective on PTC Therapeutics […] - 2025-07-30 04:22:55
- PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Analyst Upgrade
- PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $86.00. The stock had previously closed at $44.34, but opened at $47.50. Truist Financial currently has a buy rating on the stock. PTC Therapeutics shares […] - 2025-07-30 02:35:02
- New York State Common Retirement Fund Buys 2,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
- New York State Common Retirement Fund boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,421 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares […] - 2025-07-25 05:44:49
- Cerity Partners LLC Acquires Shares of 12,581 PTC Therapeutics, Inc. (NASDAQ:PTCT)
- Cerity Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,581 shares of the biopharmaceutical company’s stock, valued at approximately $641,000. A number of other institutional investors have […] - 2025-07-25 04:50:54
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
- PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and one […] - 2025-07-22 03:29:02
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Cut by Bank of New York Mellon Corp
- Bank of New York Mellon Corp lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 0.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 216,443 shares of the biopharmaceutical company’s stock after selling 439 shares during the period. […] - 2025-07-21 04:26:50
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Decreased by Teacher Retirement System of Texas
- Teacher Retirement System of Texas decreased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.9% during the first quarter, HoldingsChannel.com reports. The fund owned 18,681 shares of the biopharmaceutical company’s stock after selling 1,830 shares during the period. Teacher Retirement System of Texas’ holdings in PTC Therapeutics were worth $952,000 […] - 2025-07-15 04:24:39
- 10,287 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Allspring Global Investments Holdings LLC
- Allspring Global Investments Holdings LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the first quarter, HoldingsChannel reports. The institutional investor bought 10,287 shares of the biopharmaceutical company’s stock, valued at approximately $524,000. A number of other hedge funds have also recently bought and sold shares of PTCT. […] - 2025-07-11 04:31:12
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Diversified Trust Co
- Diversified Trust Co boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,147 shares of the biopharmaceutical company’s stock after buying an additional 329 shares during the period. […] - 2025-06-30 05:10:54
- PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial
- Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […] - 2025-06-19 02:42:49
- Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
- Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. Several other institutional […] - 2025-06-13 05:38:53
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by GAMMA Investing LLC
- GAMMA Investing LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 9,393.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,514 shares of the biopharmaceutical company’s stock after acquiring an additional 48,003 shares during the quarter. GAMMA Investing LLC’s holdings […] - 2025-06-13 04:36:51
- Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
- Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company’s stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of PTC […] - 2025-06-02 06:10:57
- Wells Fargo & Company Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $74.00
- PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $68.00 to $74.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […] - 2025-05-29 02:31:00
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a […] - 2025-05-28 04:46:51
- PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Earnings Beat
- PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $36.19, but opened at $39.40. PTC Therapeutics shares last traded at $39.92, with a volume of 455,281 shares trading hands. The biopharmaceutical company reported $10.04 […] - 2025-05-09 02:20:49
- Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $63.92
- Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has […] - 2025-05-06 02:30:48
- 48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc.
- Raymond James Financial Inc. acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, Holdings Channel reports. The firm acquired 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management […] - 2025-05-01 05:01:04
- Federated Hermes Inc. Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)
- Federated Hermes Inc. purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 47,828 shares of the biopharmaceutical company’s stock, valued at approximately $2,159,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of […] - 2025-04-14 05:15:06
- PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Reduced by Prudential Financial Inc.
- Prudential Financial Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,620 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Prudential Financial Inc.’s holdings in PTC Therapeutics were worth $254,000 at the end of the most […] - 2025-04-11 05:03:01
iShares MSCI World Small Cap UCITS ETF USD (Acc) PTCT holdings
| Date | Number of PTCT Shares Held | Base Market Value of PTCT Shares | Local Market Value of PTCT Shares | Change in PTCT Shares Held | Change in PTCT Base Value | Current Price per PTCT Share Held | Previous Price per PTCT Share Held |
|---|
| 2025-10-15 (Wednesday) | 53,282 | USD 3,650,350 | USD 3,650,350 | | | | |
| 2025-10-10 (Friday) | 52,961 | USD 3,507,607 | USD 3,507,607 | | | | |
| 2025-10-08 (Wednesday) | 52,961 | USD 3,414,925 | USD 3,414,925 | | | | |
| 2025-10-07 (Tuesday) | 52,961 | USD 3,384,473 | USD 3,384,473 | 214 | USD -33,533 | USD 63.905 | USD 64.8 |
| 2025-10-06 (Monday) | 52,747 | USD 3,418,006 | USD 3,418,006 | 0 | USD -30,065 | USD 64.8 | USD 65.37 |
| 2025-10-03 (Friday) | 52,747 | USD 3,448,071 | USD 3,448,071 | 0 | USD 123,955 | USD 65.37 | USD 63.02 |
| 2025-10-02 (Thursday) | 52,747 | USD 3,324,116 | USD 3,324,116 | 0 | USD 53,275 | USD 63.02 | USD 62.01 |
| 2025-10-01 (Wednesday) | 52,747 | USD 3,270,841 | USD 3,270,841 | 0 | USD 33,758 | USD 62.01 | USD 61.37 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of PTCT by Blackrock for IE00BF4RFH31
Show aggregate share trades of PTCT| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 214 | | | 63.905* | | 48.73 |
| 2025-09-08 | SELL | -428 | | | 56.950* | | 48.00 Profit of 20,542 on sale |
| 2025-08-15 | BUY | 216 | | | 48.820* | | 47.99 |
| 2025-08-07 | BUY | 648 | | | 50.360* | | 47.97 |
| 2025-07-29 | BUY | 216 | | | 49.290* | | 47.85 |
| 2025-07-14 | BUY | 432 | | | 49.460* | | 47.86 |
| 2025-06-30 | BUY | 432 | | | 48.840* | | 47.82 |
| 2025-06-25 | BUY | 648 | | | 48.890* | | 47.79 |
| 2025-06-20 | SELL | -108 | | | 50.200* | | 47.74 Profit of 5,156 on sale |
| 2025-06-12 | SELL | -864 | | | 50.980* | | 47.60 Profit of 41,124 on sale |
| 2025-06-02 | BUY | 327 | | | 48.830* | | 47.38 |
| 2025-05-28 | BUY | 218 | | | 47.280* | | 47.35 |
| 2025-05-14 | BUY | 108 | | | 46.750* | | 47.44 |
| 2025-05-13 | BUY | 216 | | | 46.390* | | 47.45 |
| 2025-05-07 | BUY | 324 | | | 40.760* | | 47.60 |
| 2025-04-28 | BUY | 108 | | | 49.760* | | 47.68 |
| 2025-04-16 | BUY | 1,404 | | | 46.410* | | 47.62 |
| 2025-04-14 | BUY | 216 | | | 45.080* | | 47.66 |
| 2025-04-08 | SELL | -218 | | | 39.770* | | 47.94 Profit of 10,452 on sale |
| 2025-04-04 | SELL | -218 | | | 43.240* | | 48.06 Profit of 10,477 on sale |
| 2025-03-28 | BUY | 1,080 | | | 54.240* | | 47.96 |
| 2025-03-12 | SELL | -216 | | | 53.610* | | 46.62 Profit of 10,071 on sale |
| 2025-03-04 | SELL | -216 | | | 51.800* | | 46.18 Profit of 9,975 on sale |
| 2025-02-26 | SELL | -436 | | | 50.960* | | 45.77 Profit of 19,954 on sale |
| 2025-02-13 | BUY | 5,406 | | | 49.670* | | 44.93 |
| 2025-02-12 | BUY | 388 | | | 48.930* | | 44.85 |
| 2025-01-27 | BUY | 97 | | | 46.070* | | 43.86 |
| 2025-01-23 | BUY | 97 | | | 46.180* | | 43.73 |
| 2024-12-09 | BUY | 3,492 | | | 48.060* | | 43.31 |
| 2024-12-04 | BUY | 194 | | | 49.860* | | 42.75 |
| 2024-12-03 | BUY | 291 | | | 50.290* | | 42.48 |
| 2024-11-19 | BUY | 588 | | | 39.360* | | 41.49 |
| 2024-11-18 | BUY | 196 | | | 39.230* | | 41.62 |
| 2024-11-12 | BUY | 388 | | | 44.620* | | 41.44 |
| 2024-11-11 | BUY | 97 | | | 44.870* | | 41.21 |
| 2024-11-07 | BUY | 485 | | | 42.960* | | 40.84 |
| 2024-10-23 | BUY | 194 | | | 42.480* | | 38.88 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of PTCT
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 134,897 | 0 | 383,223 | 35.2% |
| 2025-09-18 | 283,349 | 0 | 426,438 | 66.4% |
| 2025-09-17 | 1,027,794 | 0 | 1,194,008 | 86.1% |
| 2025-09-16 | 193,375 | 0 | 307,403 | 62.9% |
| 2025-09-15 | 322,719 | 9 | 534,139 | 60.4% |
| 2025-09-12 | 385,453 | 74 | 562,965 | 68.5% |
| 2025-09-11 | 284,284 | 0 | 452,606 | 62.8% |
| 2025-09-10 | 278,555 | 4 | 408,673 | 68.2% |
| 2025-09-09 | 468,278 | 0 | 688,805 | 68.0% |
| 2025-09-08 | 283,827 | 0 | 420,017 | 67.6% |
| 2025-09-05 | 346,662 | 0 | 658,628 | 52.6% |
| 2025-09-04 | 461,616 | 1,570 | 706,327 | 65.4% |
| 2025-09-03 | 500,004 | 50 | 703,685 | 71.1% |
| 2025-09-02 | 410,808 | 361 | 623,975 | 65.8% |
| 2025-08-29 | 260,928 | 500 | 368,011 | 70.9% |
| 2025-08-28 | 169,376 | 0 | 286,545 | 59.1% |
| 2025-08-27 | 117,557 | 0 | 225,793 | 52.1% |
| 2025-08-26 | 159,756 | 0 | 292,412 | 54.6% |
| 2025-08-25 | 184,388 | 3 | 278,802 | 66.1% |
| 2025-08-22 | 212,292 | 0 | 337,121 | 63.0% |
| 2025-08-21 | 110,090 | 0 | 199,278 | 55.2% |
| 2025-08-20 | 214,864 | 0 | 342,111 | 62.8% |
| 2025-08-19 | 574,175 | 77 | 1,073,506 | 53.5% |
| 2025-08-18 | 264,556 | 175 | 600,473 | 44.1% |
| 2025-08-15 | 276,236 | 0 | 451,337 | 61.2% |
| 2025-08-14 | 261,106 | 0 | 447,801 | 58.3% |
| 2025-08-13 | 429,197 | 0 | 681,304 | 63.0% |
| 2025-08-12 | 174,739 | 0 | 313,209 | 55.8% |
| 2025-08-11 | 186,874 | 6,675 | 467,511 | 40.0% |
| 2025-08-08 | 428,325 | 1,746 | 852,881 | 50.2% |
| 2025-08-07 | 147,599 | 144 | 300,021 | 49.2% |
| 2025-08-06 | 82,600 | 20 | 193,167 | 42.8% |
| 2025-08-05 | 182,572 | 112 | 369,257 | 49.4% |
| 2025-08-04 | 134,469 | 0 | 278,380 | 48.3% |
| 2025-08-01 | 173,470 | 0 | 295,786 | 58.6% |
| 2025-07-31 | 371,852 | 50 | 836,679 | 44.4% |
| 2025-07-30 | 349,322 | 75 | 666,752 | 52.4% |
| 2025-07-29 | 539,007 | 258 | 1,083,836 | 49.7% |
| 2025-07-28 | 238,893 | 0 | 371,803 | 64.3% |
| 2025-07-25 | 273,787 | 0 | 463,683 | 59.0% |
| 2025-07-24 | 95,248 | 40 | 211,840 | 45.0% |
| 2025-07-23 | 117,827 | 0 | 221,680 | 53.2% |
| 2025-07-22 | 199,716 | 0 | 323,578 | 61.7% |
| 2025-07-21 | 108,853 | 0 | 162,439 | 67.0% |
| 2025-07-18 | 122,037 | 0 | 172,363 | 70.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.